62
Participants
Start Date
October 7, 2025
Primary Completion Date
May 31, 2027
Study Completion Date
June 3, 2027
Elranatamab
Specified dose on specified days
Mezigdomide
Specified dose on specified days
Dexamethasone
Specified dose on specified days
NOT_YET_RECRUITING
Local Institution - 0017, Trondheim
NOT_YET_RECRUITING
Local Institution - 0013, Hamburg
NOT_YET_RECRUITING
Local Institution - 0022, Salamanca
NOT_YET_RECRUITING
Local Institution - 0021, Santander
RECRUITING
University of Texas MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
Local Institution - 0031, Shanghai
NOT_YET_RECRUITING
Local Institution - 0030, Suzhou
NOT_YET_RECRUITING
Local Institution - 0001, Birmingham
NOT_YET_RECRUITING
Local Institution - 0029, New Haven
NOT_YET_RECRUITING
Local Institution - 0028, Hackensack
NOT_YET_RECRUITING
Local Institution - 0032, Calgary
NOT_YET_RECRUITING
Local Institution - 0026, Vancouver
NOT_YET_RECRUITING
Local Institution - 0027, Halifax
RECRUITING
Princess Margaret Cancer Centre, Toronto
NOT_YET_RECRUITING
Local Institution - 0015, Dresden
NOT_YET_RECRUITING
Local Institution - 0014, Heidelberg
NOT_YET_RECRUITING
Local Institution - 0011, Athens
NOT_YET_RECRUITING
Local Institution - 0012, Athens
NOT_YET_RECRUITING
Local Institution - 0019, Oslo
NOT_YET_RECRUITING
Local Institution - 0016, London
NOT_YET_RECRUITING
Local Institution - 0018, London
NOT_YET_RECRUITING
Local Institution - 0020, Manchester
Lead Sponsor
Celgene
INDUSTRY